MX343356B - Toxinas proteicas recombinantes de alto nivel de expresion. - Google Patents

Toxinas proteicas recombinantes de alto nivel de expresion.

Info

Publication number
MX343356B
MX343356B MX2012011103A MX2012011103A MX343356B MX 343356 B MX343356 B MX 343356B MX 2012011103 A MX2012011103 A MX 2012011103A MX 2012011103 A MX2012011103 A MX 2012011103A MX 343356 B MX343356 B MX 343356B
Authority
MX
Mexico
Prior art keywords
high level
toxin
level expression
recombinant toxin
toxin proteins
Prior art date
Application number
MX2012011103A
Other languages
English (en)
Other versions
MX2012011103A (es
Inventor
W Talbot Henry
Chew Lawrence
M Retallack Diane
Jin Hongfan
Original Assignee
Pfenex Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44763483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343356(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2010/030573 external-priority patent/WO2011123139A1/en
Application filed by Pfenex Inc * filed Critical Pfenex Inc *
Publication of MX2012011103A publication Critical patent/MX2012011103A/es
Publication of MX343356B publication Critical patent/MX343356B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin

Abstract

La presente invención se refiere a un método para producir una toxina protéica recombinante en una célula hospedera de Pseudomonas, dicho método que comprende: ligar en un vector de expresión una secuencia de nucleótidos que codifica una toxina protéica, en donde la secuencia de nucleótidos que codifica la toxina proteína se fusiona a una secuencia que codifica la señal de secreción que es Azu, IbpS31A, o Cupa2, y que CupA2, y que cuando se expresa dirige la transferencia de la toxina protéica al periplasma transformar la célula hospedera de Pseudomonas con el vector de expresión; y cultivar la célula hospedera de Pseudomonas transformada en un medio de cultivo adecuado para la expresión de la toxina protéica recombinante; en donde la toxina protéica recombinante es CRM197, producida a un rendimiento de toxina protéica soluble CRM197 y/o activa de 0.2 gramos por litro a 12 gramos por litro.
MX2012011103A 2010-03-30 2011-03-28 Toxinas proteicas recombinantes de alto nivel de expresion. MX343356B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31915210P 2010-03-30 2010-03-30
PCT/US2010/030573 WO2011123139A1 (en) 2010-03-30 2010-04-09 High level expression of recombinant crm197
US32523510P 2010-04-16 2010-04-16
PCT/US2011/030227 WO2011126811A2 (en) 2010-03-30 2011-03-28 High level expression of recombinant toxin proteins

Publications (2)

Publication Number Publication Date
MX2012011103A MX2012011103A (es) 2015-05-15
MX343356B true MX343356B (es) 2016-11-03

Family

ID=44763483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011103A MX343356B (es) 2010-03-30 2011-03-28 Toxinas proteicas recombinantes de alto nivel de expresion.

Country Status (11)

Country Link
US (3) US8530171B2 (es)
EP (1) EP2553102B1 (es)
JP (1) JP5839411B2 (es)
KR (1) KR20130072201A (es)
CN (1) CN102869778B (es)
AU (1) AU2011238711B2 (es)
BR (1) BR112012024898A2 (es)
CA (1) CA2793978C (es)
MX (1) MX343356B (es)
NZ (1) NZ602958A (es)
WO (1) WO2011126811A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020059A2 (en) 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현
RU2754446C2 (ru) 2011-04-22 2021-09-02 ВАЙЕТ ЭлЭлСи Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
WO2013084071A2 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
EP2869838B1 (en) * 2012-07-05 2020-09-02 Children's Medical Center Corporation The bacterial biofilm matrix as a platform for protein delivery
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CN104140972B (zh) * 2013-05-07 2018-01-23 上海惠盾生物技术有限公司 白喉毒素突变体crm197的制备方法
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
WO2015117093A1 (en) * 2014-01-31 2015-08-06 Fina Biosolutions, Llc Expression and purification of crm197 and related proteins
US10597664B2 (en) * 2014-01-31 2020-03-24 Fina Biosolutions, Llc Expression and purification of CRM proteins and related proteins, and protein domains
US11060123B2 (en) 2014-01-31 2021-07-13 Fina Biosolutions, Llc Production of soluble recombinant protein without n-terminal methionine
EP3221339A1 (en) 2014-11-20 2017-09-27 Biological E Limited Codon optimized polynucleotide for high level expression of crm197
BR112018069945A2 (pt) * 2016-04-06 2019-02-05 Plant Health Care Inc micróbios benéficos para distribuição de peptídeos ou proteínas efetoras e uso dos mesmos
US11071779B2 (en) 2016-06-17 2021-07-27 Children's Medical Center Corporation Biofilm matrix-boosted vaccine
RU2636346C1 (ru) * 2016-07-01 2017-11-22 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Способ получения рекомбинантного экзопротеина А Pseudomonas aeruginosa
KR101908590B1 (ko) 2017-02-01 2018-10-16 (주)포바이오코리아 Crm197의 용해성 단백질 발현 및 정제 방법
EP3444269A1 (en) 2017-08-17 2019-02-20 National Research Council of Canada Systems and methods for the production of diphtheria toxin polypeptides
US10787671B2 (en) 2017-10-27 2020-09-29 Pfenex Inc. Method for production of recombinant Erwinia asparaginase
AU2018354069A1 (en) * 2017-10-27 2020-06-11 Pelican Technology Holdings, Inc. Bacterial leader sequences for periplasmic protein expression
US10662433B2 (en) 2017-10-27 2020-05-26 Pfenex Inc. Method for production of recombinant E. coli asparaginase
CN112513066A (zh) * 2018-01-19 2021-03-16 台湾浩鼎生技股份有限公司 Crm197蛋白质表达
US10829731B2 (en) * 2018-01-25 2020-11-10 Alliance For Sustainable Energy, Llc Biocatalysts for conversion of thermochemical waste streams
KR102475419B1 (ko) * 2018-07-16 2022-12-07 주식회사 유바이오로직스 Crm197을 고농도로 발현하는 코리네박테리움 균주
EP3893870A1 (en) 2018-12-13 2021-10-20 Huya Bioscience International LLC Sulcardine administration for treatment of acute atrial fibrillation
BR112022006851A2 (pt) * 2019-10-14 2022-07-05 Syngenta Crop Protection Ag Proteínas inseticidas
BE1029145B1 (fr) * 2021-02-26 2022-09-27 Curavac Europe Methode de production d'une forme periplasmique de la proteine crm197
US20220313798A1 (en) 2021-03-30 2022-10-06 Jazz Pharmaceuticals Ireland Ltd. Dosing of recombinant l-asparaginase
CN113201473B (zh) * 2021-04-22 2022-06-07 广东省科学院微生物研究所(广东省微生物分析检测中心) 香茅醇在制备促进铜绿假单胞菌毒力基因toxA表达的制剂中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
CH660375A5 (it) 1983-02-08 1987-04-15 Sclavo Spa Procedimento per la produzione di proteine correlate alla tossina difterica.
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4830962A (en) * 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
GB8517071D0 (en) 1985-07-05 1985-08-14 Hoffmann La Roche Gram-positive expression control sequence
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
KR0168039B1 (ko) 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
US6043057A (en) 1988-09-16 2000-03-28 Vitec Aktiebolag Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
WO1990009444A1 (en) * 1989-02-10 1990-08-23 Genesit Oy A method for producing pertussis toxin subunits
US7232671B2 (en) 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
EP0396964B1 (en) 1989-04-28 1995-09-06 SCLAVO S.p.A. Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
GB8914122D0 (en) 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
US5834246A (en) 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
DE69002817T2 (de) 1989-11-28 1993-12-09 Wellcome Found Vakzine.
US5935580A (en) 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
ES2231770T3 (es) 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
DE69434000T3 (de) 1993-10-05 2008-11-06 UCB Pharma Ltd., Slough Impfstoffzusammensetzungen
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
US5932714A (en) 1995-02-23 1999-08-03 Connaught Laboratories Limited Expression of gene products from genetically manipulated strains of Bordetella
WO1997002836A1 (en) 1995-07-07 1997-01-30 Oravax, Inc. Clostridium difficile toxins as mucosal adjuvants
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
GB9904582D0 (en) 1999-02-26 1999-04-21 Nycomed Imaging As Process
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1343870A4 (en) 2000-11-09 2005-07-13 Univ Queensland BACTERIAL EXPRESSION SYSTEMS
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20060246036A1 (en) 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CA2530363C (en) 2003-06-23 2013-05-07 Baxter International Inc. Carrier proteins for vaccines
AU2004285558A1 (en) 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain
CN1906294B (zh) 2003-11-19 2013-09-11 陶氏环球技术公司 改良的蛋白表达系统
PL2336153T3 (pl) 2003-11-21 2016-08-31 Pfenex Inc Udoskonalone systemy ekspresji z układem wydzielania SEC
US20110097359A1 (en) 2003-12-12 2011-04-28 Tim Lee Production of diphtheria toxin
WO2005069913A2 (en) * 2004-01-16 2005-08-04 Dow Global Technologies Inc. Expression of mammalian proteins in pseudomonas fluorescens
BRPI0513826A2 (pt) * 2004-07-26 2010-06-22 Dow Global Technologies Inc processo para expressão de proteìna melhorada através de engenharia de cepa
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
JP2009538622A (ja) 2006-05-30 2009-11-12 ダウ グローバル テクノロジーズ インコーポレイティド コドン最適化法
CN101500581B (zh) 2006-06-08 2013-10-30 科内尔研究基金会 编码艰难梭菌毒素a和毒素b受体结合域的密码子优化dna分子及其使用方法
BRPI0807834A2 (pt) 2007-01-31 2014-07-22 Dow Global Technologies Inc " sequências-líder bacterianas para expressão aumentada ".
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101688213A (zh) * 2007-04-27 2010-03-31 陶氏环球技术公司 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法
WO2010008764A1 (en) * 2008-06-23 2010-01-21 Dow Global Technologies Inc. Pseudomonas fluorescens strains for production of extracellular recombinant protein
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
KR20130072201A (ko) 2010-03-30 2013-07-01 피페넥스 인크. 재조합 독소 단백질의 고수준 발현

Also Published As

Publication number Publication date
JP2013529064A (ja) 2013-07-18
AU2011238711B2 (en) 2015-06-18
US8906636B2 (en) 2014-12-09
WO2011126811A2 (en) 2011-10-13
EP2553102A2 (en) 2013-02-06
US20140051093A1 (en) 2014-02-20
EP2553102A4 (en) 2013-10-23
WO2011126811A3 (en) 2012-03-08
EP2553102B1 (en) 2015-12-09
US20110287443A1 (en) 2011-11-24
JP5839411B2 (ja) 2016-01-06
CA2793978C (en) 2021-08-03
CN102869778B (zh) 2015-05-20
NZ602958A (en) 2014-07-25
MX2012011103A (es) 2015-05-15
CN102869778A (zh) 2013-01-09
AU2011238711A1 (en) 2012-11-08
KR20130072201A (ko) 2013-07-01
US8530171B2 (en) 2013-09-10
US20150361405A1 (en) 2015-12-17
CA2793978A1 (en) 2011-10-13
BR112012024898A2 (pt) 2015-10-06

Similar Documents

Publication Publication Date Title
MX343356B (es) Toxinas proteicas recombinantes de alto nivel de expresion.
BR112012007984A2 (pt) polinucleotídeo, vetor, célula hospedeira, polipeptídeo, processos para preparar uma toxina bacteriana, para a expressão periplásmica de um polipeptídeo recombinante, para fabricar um conjugado e uma vacina
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
MX2021006714A (es) Neurotoxinas cationicas.
NZ703378A (en) Degradable clostridial toxins
PH12018501517B1 (en) Neisseria meningitidis compositions and methods thereof
MY168208A (en) Recombinant microorganisms and uses therefor
MY157111A (en) Recombinant microorganisms and methods of production thereof
WO2012003474A3 (en) Compositions and methods related to protein a (spa) variants
EA035991B9 (ru) Новый полисахарид и его применения
MX351448B (es) Enzimas de clostridium histolyticum y métodos para el uso de los mismos.
MX2010004305A (es) Plantas que tienen rasgos relacionados con el rendimiento aumentado y un metodo para producirlas.
MY156849A (en) Novel lactobacillus plantarum and composition comprising the same
MX367024B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
EP3162894A3 (en) Methods for the manufacture of proteolytically processed polypeptides
AU2015348922A8 (en) Codon optimized polynucleotide for high level expression of CRM197
MX2010002867A (es) Cepas de micoplasma atenuadas vivas.
MX2010008555A (es) Bacteria recombinante con sistema de secrecion de hemolisina de e-coli y expresion incrementada y/o secrecion de hiya. proceso de elaboracion y usos de la misma.
PH12017502215A1 (en) Recombinant microorganism for improve production of fine chemicals
WO2010093182A3 (ko) Ｌ-아미노산 생산용 미생물 및 이를 이용하여 ｌ-아미노산을 생산하는 방법
PH12017502240A1 (en) Recombinant microorganism for improved production of alanine
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
GB201000588D0 (en) Bacterial host strain
MX347978B (es) Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.

Legal Events

Date Code Title Description
FG Grant or registration